Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 3/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491658 | 1.00 | TAS1R3 (0.51) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL18510828 | 0.94 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL20149818 | 0.94 | TAS1R3 (0.53) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL18954932 | 0.94 | ALDH1A1 (0.55) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL18954935 | 0.94 | ALDH1A1 (0.55) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL19503072 | 0.94 | ALDH1A1 (0.55) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL20149814 | 0.92 | KDM4E (0.48) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL25496782 | 0.91 | KDM4E (0.51) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL23630081 | 0.89 | KDM4E (0.54) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A | |
| SCHEMBL23630085 | 0.89 | KDM4E (0.54) | TAS1R3TAS1R1KDM4EALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | TAS1R3 4579/4885TAS1R1 4780/4885KDM4E 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.